C burnetii seropositivity in AIDS-NHL cases and HIV-infected controls
| Patient group . | ELISA . | IFA . | Percent positive‡ . | Adjusted OR§ (95% confidence interval) . | |||||
|---|---|---|---|---|---|---|---|---|---|
| (–) . | B . | (+) . | Total . | (–) . | (+)* . | Total† . | |||
| HIV-infected controls | 61 | 4 | 2 | 67 | 0 | 6 | 6 | 9 | |
| AIDS-NHL cases | |||||||||
| Incident | 27 | 1 | 1 | 29 | 0 | 2 | 2 | 7 | 0.85 (0.15-4.66) |
| Prevalent | 36 | 2 | 1 | 39 | 0 | 3 | 3 | 8 | 1.04 (0.23-4.70) |
| Incident + prevalent | 63 | 3 | 2 | 68 | 0 | 5 | 5 | 7 | 0.82 (0.24-2.85) |
| Patient group . | ELISA . | IFA . | Percent positive‡ . | Adjusted OR§ (95% confidence interval) . | |||||
|---|---|---|---|---|---|---|---|---|---|
| (–) . | B . | (+) . | Total . | (–) . | (+)* . | Total† . | |||
| HIV-infected controls | 61 | 4 | 2 | 67 | 0 | 6 | 6 | 9 | |
| AIDS-NHL cases | |||||||||
| Incident | 27 | 1 | 1 | 29 | 0 | 2 | 2 | 7 | 0.85 (0.15-4.66) |
| Prevalent | 36 | 2 | 1 | 39 | 0 | 3 | 3 | 8 | 1.04 (0.23-4.70) |
| Incident + prevalent | 63 | 3 | 2 | 68 | 0 | 5 | 5 | 7 | 0.82 (0.24-2.85) |
B, borderline.
Titers ≥1:16 were considered positive.
Only samples with borderline or positive ELISA results were validated by IFA.
Calculated as number of IFA-validated positive samples divided by total samples.
ORs for C burnetii seropositivity adjusted for age at blood collection, sex, race/ethnicity, CD4 counts, and cohort.